Cross-Sectional (n=584)
Yes
There is significant heterogeneity in the prescription and laboratory testing of natriuretic peptides in France, highlighting the need for careful interpretation and standardization.
National survey shows heterogeneous NP assay practices in France; leaves open need for standardization and outcome studies.
Since the introduction of routine assay for natriuretic peptides (NP), there is an increasing number of clinical applications for these assays. Due to the continuously increasing number of prescription of those tests, a reappraisal of the use of natriuretic peptide assays, namely BNP and NT-proBNP in France was necessary. This was achieved through a national survey to obtain a detailed description of NP prescription and realization by French laboratories. A questionnaire was sent in April 2010 to hospital and private clinical chemists. Statistical analysis of results concerned 584 answers. This survey demonstrated an equivalent use of BNP and NT-proBNP both in public or private laboratories together with a huge heterogeneity of tests used within labs. Medical prescription heterogeneity both in public or private sectors confirms the large implication of those tests in clinical diagnosis. These assays are not yet standardized, so clinicians and biologists should be very careful when interpreting the results for diagnostic or therapeutic monitoring.
No takes yet. Share an insight, caveat, or question.
Collin‐Chavagnac et al. (2011) conducted a cross-sectional in Natriuretic peptide assay utilization (n=584). Natriuretic peptide assays (BNP and NT-proBNP) was evaluated on Prescription and realization of natriuretic peptide assays.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: